



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2024 #30

September 6, 2024

INSIDE:

WORD IN WASHINGTON	2
PEOPLE	3
MEMBER NEWS	3
ABC WELC Webinar Set for September 26 th	4
ABC Talking Points on Importance of Community Blood Centers	4
ABC Announces Cybersecurity Webinar on September 17 th	4
Speakers Announced for 2024 ADRP Master Class	4
Register for ABC WELC Rise & Lead Workshop ..	5
RESEARCH IN BRIEF	5
GLOBAL NEWS	6
COMPANY NEWS	6
CALENDAR	7
POSITIONS	8

Blood Community Joint Comments to CMS Regarding LTOWB

America's Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross (ARC) have provided [comments](#) in response to CMS' [proposal](#), "to add the administration of low titer O positive whole blood (LTOWB) transfusion to the current list of advanced life support, level 2 (ALS2) procedures."

In the joint comments, the blood community expresses concern that CMS' proposed policy, "will not achieve the intended outcome of ensuring that patients have access to prehospital blood transfusions." Specifically, ABC, AABB, and ARC outline that the proposed policy is flawed because:

- "it does not apply to all FDA-approved blood and blood components that are critical for patients requiring prehospital hemostatic resuscitation; and
- the current payment rate for ALS2 is far too low to accommodate the cost of providing pre-hospital blood transfusions."

The blood community comments also state that, "CMS should consider a model that includes a prehospital blood product add-on payment that incorporates the costs associated with procuring, storing, and administering blood transfusions. Activities may include, but are not limited to, procuring blood products from entities such as blood collection establishments and hospitals, storing blood products in accordance with safety standards, and transfusing the blood safely and effectively."

CMS previously proposed a [rule](#) that included recognition of LTOWB transfusion as part of the Ambulance Fee Schedule (AFS). CMS explicitly noted in the proposed rule that, "we do not have the authority to provide an additional payment, such as an add-on payment for the administration of whole blood transfusion therapy (WBT) under the AFS." The agency also stated that most ambulances that carry blood would already be classified as advanced life support level 2 (ALS2), and therefore the expected impact is minimal.

ABC will continue to provide updates on its advocacy efforts as they become available. ABC members are encouraged to contact ABC Vice President of Government Affairs [Diane Calmus, JD](#) with questions or to provide feedback.

(Source: Blood Community [Joint Comments](#), 9/3/24) 💧

Rise & Lead
A WOMEN'S LEADERSHIP WORKSHOP

Elevate your leadership journey!
Join us in San Antonio, TX
November 6th & 7th
[Register Now](#)



WORD IN WASHINGTON

The Health Resources and Services Administration (HRSA) has officially [announced](#) that the, “Organ Procurement and Transplantation Network (OPTN) Board of Directors, the governing board that develops national organ allocation policy, is now separately incorporated and independent from the Board of long-time OPTN contractor, the United Network for Organ Sharing (UNOS).” Additionally, the agency has also awarded, “an OPTN Board Support contract to [the] American Institutes for Research to support the newly incorporated OPTN Board of Directors.” According to a HRSA news release, these actions are aimed at, “better serv[ing] patients by breaking up the monopoly that ran the nation’s organ allocation system [as] part of the OPTN [modernization plan](#) announced by HRSA in March 2023. Prior to these steps, the national body responsible for developing organ allocation policy for the country, the OPTN, and the corporate entity contracted to implement the policy, UNOS, shared the exact same Board of Directors. The new board support contractor will be accountable to HRSA and will organize a special election for a new OPTN Board of Directors with a focus on eliminating conflicts of interest and ensuring that data, evidence, and the voices of clinical leaders, scientific experts, patients, and donor families are driving action and accountability. Moving forward, no member of the OPTN Board can sit on an OPTN vendor’s board of directors.” HRSA also explained in the news release that, “[t]he OPTN Board Support contract awarded today will not only support the work associated with a new board election but also will provide logistical and governance support to the OPTN Board of Directors to improve the accountability and transparency of OPTN policymaking and governance processes. Additional separate, multi-vendor contracts to manage various functions of the OPTN will be awarded in the coming months.”

(Source: HRSA [News Release](#), 8/29/24)

The *Associated Press* (AP) [published](#) a story this week highlighting that the U.S. Food and Drug Administration (FDA) inspections of pharmaceutical manufacturing facilities are, “still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the U.S. and across the world.” According to the article, the AP analyzed FDA data that, “shows that agency staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance inspections since before the pandemic, raising the risks of contamination and other issues in drugs used by millions of Americans. The firms that are overdue for safety and quality inspections represent about 42 percent of the 4,700 plants that are currently registered to produce drugs for the U.S. and previously underwent FDA review before May 2019, the AP found. The plants make hundreds of critical medicines, including antibiotics, blood thinners and cancer therapies.” The FDA responded in the article that, “[t]he U.S. drug supply is the safest on the planet and no other regulator conducts more inspections than the FDA [noting] that the agency has increased drug inspections each year since 2021 while prioritizing foreign factories.”

(Source: *Associated Press*, “[FDA has massive backlog of factory inspections as staffers leave for private sector jobs](#), 9/6/24) 💧

The ABC Newsletter (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2024 by America’s Blood Centers. Reproduction of the ABC Newsletter is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Jed Gorlin

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$420

Send subscription queries to

memberservices@americasblood.org

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.


PEOPLE



The U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) met this week to discuss and vote on recommendations related to tissue biovigilance. Committee members from America's Blood Centers (ABC) member centers that participated in the meeting included: **Daniela Hermelin, MD**, chief medical officer (CMO) at ImpactLife, **Suchi Pandey, MD**, CMO at Stanford Blood Center, **Stacy Sime**, president and chief executive officer (CEO) at Life-Serve Blood Center and Chair of the ABC Policy Council, **Diane Wilson, BSN, MSN/MHA**, chief operating officer and executive vice president at Solvita, in addition to **Jed Gorlin, MD, MBA**, CMO at ABC and vice president of Medical and Quality Affairs for New York Blood Center Enterprises. ♦

MEMBER NEWS

Solvita recently [announced](#), “the construction of a large-scale solar panel installation at Solvita Kettering Research Park that will help power tissue graft manufacturing and further the company’s growth.” Known as, “‘Project Sol Array,’ Solvita is partnering with IGS Solar, a division of central Ohio-based IGS Energy, [who] will build, own and operate the 1.5-megawatt solar array on Solvita’s KRP property with no upfront cost to Solvita. IGS will sell all the electricity the system produces to Solvita under a long-term power purchase agreement.” Solvita Chief Executive Officer Christopher Graham, MBA added in the news release, “[w]e remind everyone that ‘Sol’ in our name means ‘sun’ and ‘vita’ means ‘life.’ We are using the sun as part of our long-term strategy to manage our use and expense of energy and demonstrate our commitment to helping solve problems and improving our world.” This initiative will make Solvita, “the first major tissue bank in the world to use a solar array to power a portion of its operations. [The organization] expects Project Sol Array to be generating useful power by late 2025.”



(Source: Solvita [News Release](#), 8/29/24) ♦





America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

ABC WELC Webinar Set for September 26th

The next America's Blood Centers (ABC) Women's Executive Leadership Community (WELC) Webinar: "Authentic Confidence" will take place on September 26th at 3 p.m. EDT. The featured speaker for this webinar is Brian Rollefson, founder of Live Wide Leadership and vice president of Human Resources and Organizational Infrastructure at The Community Blood Center. This interactive program will guide participants on their confidence-building journey, providing tools and insights to leverage your inherent strengths, resolve areas for development, and propel yourself to your maximum potential. Through an intuitive confidence profile assessment, participants will increase their self-awareness, leading to stronger relationships, better communication, and transformation from inner critic to future influencer. More information and link to registration are available to ABC members [here](#).

ABC Talking Points on Importance of Community Blood Centers

ABC has published [talking points](#) that highlight the importance of community blood centers and their unique role in meeting the constant demand for blood transfusions. ABC members can access this document and ABC's talking points library on [CollABORate](#). These talking points can be customized and used with stakeholders.

ABC Announces Cybersecurity Webinar on September 17th

The next ABC Education Committee Webinar titled "Cybersecurity: Threats & Preventative Actions" will occur September 17th at 3 p.m. EDT. The webinar will cover the topics of threat landscape and best practices for the prevention of cyberattacks. Featured speakers include George Chacko, CISSP, HCSSP, PMP, executive director of Information Security and Compliance at the New York Blood Center Enterprises and Saiyed Iqbal, CRISC, CGEIT, CNE, director of Information Services at LifeStream. More information and a link to registration are available [here](#).

Speakers Announced for 2024 ADRP Master Class

The full schedule of speakers is [available](#) for the 2024 ADRP Master Class: "Bring in the Coach — The Path to Effective Leadership!" [Register now](#) and do not miss your shot to grow and learn. This virtual event is taking place September 18th-19th and will include:

- Health Psychologist Nicole Eull;
- Leadership Coach Jonathan R. Parker;
- Leadership Expert William B. Henry; and
- Business Strategy and Development Leader Dr. Meghan Kinter.

The [2024 Master Class](#) promises an interactive journey filled with powerful insights, practical tools, and actionable strategies. Gain the skills you need to enhance communication, build effective teamwork, and

(continued on page 5)



INSIDE ABC (continued from page 4)

boost emotional intelligence. This is your opportunity to leave the bench and master effective leadership. Secure your spot today and equip yourself with the knowledge and expertise needed to lead your team to victory. When we thrive, patients thrive. Grab your clipboard, [register today](#), and get ready to elevate your team to new heights!

Register for ABC WELC Rise & Lead Workshop

[Registration](#) is open for the ABC Women's Executive Leadership Community's (WELC) [Rise & Lead Workshop](#). This event will take place November 6th -7th in San Antonio, Texas at the Hyatt Regency Hill Country Resort. The workshop will ignite meaningful conversations and cultivate diverse perspectives. This event goes beyond traditional conferences by encouraging dynamic conversations that spark connections and drive personal and professional growth. At the Rise & Lead Workshop, you will delve into topics that matter, participate in interactive networking sessions, and walk away with tangible, real-life strategies to become a more resilient leader in today's ever-evolving world. Elevate your leadership journey with us! A [preliminary agenda](#) is available. [Book](#) your room by October 9th to secure the group rate. 💧

RESEARCH IN BRIEF

Is Washing Red Blood Cells for Neonatal Cardiac Surgery Beneficial? A study [published](#) in *Vox Sanguinis* "aimed to investigate whether cardiopulmonary bypass (CPB) priming with washed red blood cells (RBCs) improves outcomes in neonates undergoing cardiac surgery." The authors noted that, "[n]eonates undergoing elective cardiac CPB surgery were (N=101) divided into washed (N=45) and unwashed (N=56) groups [and inclusion] criteria were elective cardiac CPB surgery, age ≤ 28 days and CPB duration of 1–3 hours." The researchers explained that for this study, "[t]he primary outcome measures were changes in the patients' internal environment, circulatory system and inflammatory mediators during the perioperative period...While no significant difference was observed in total RBCs transfused or maximum flow rate, peak hematocrit (Hct) and peak hemoglobin (Hb) (100.00 vs. 91.00 g/L, $p = 0.04$) were elevated in the washed group." The paper stated that, "[d]uring the CPB rewarming, the oxygen delivery index of the washed group was significantly higher ($p < 0.05$) [and the] washed group demonstrated significantly lower lactate values at the end of CPB (2.30 vs. 3.15 mmol/L, $p < 0.01$)." The study found that, "[a]dditionally, the incidence of hyperlactatemia at the end of CPB was significantly lower in the washed group ($p = 0.04$)...The rate of delayed chest closure was significantly lower in the washed group (16 vs. 2 percent, $p = 0.02$)...Preoperatively, only Interferon- γ differed significantly between groups (2.22 vs. 1.45 pg/mL, $p < 0.01$)." The authors noted that, "[t]umor necrosis factor- α was significantly higher in the washed group compared with the unwashed group (2.28 vs. 1.64 pg/mL, $p < 0.05$)...D-dimer, fibrinogen and fibrin degradation products increased significantly in both groups compared with baseline." The study concluded that this particular RBC washer, "can effectively increase Hb and Hct levels and remove RBC metabolites...However, this intervention did not significantly improve intraoperative changes in the inflammatory and coagulation systems [and] there was no difference in in-hospital mortality between the two groups ($p = 0.50$), suggesting that priming RBCs washing may only affect early postoperative outcomes."

Citation: Wang, H., Jin, Y., Gao, P., *et al.* "[Is it useful to wash stored red blood cells in cardiopulmonary bypass priming fluid for neonatal cardiac surgery? A single-center retrospective study.](#)" *Vox Sanguinis*. 2024.

Contributed by Richard Gammon, MD, Chief Medical Officer at Carter BloodCare 💧



GLOBAL NEWS

The World Health Organization (WHO) has [announced](#) the publication of a document titled, “[WHO Global Framework to Define and Guide Studies into the Origins of Emerging and Re-emerging Pathogens with Epidemic and Pandemic Potential](#).” According to the WHO, the framework aims to serve as a tool offering a, “unified, structured approach to investigating the origins of a novel pathogen” when investigating infectious disease outbreaks. It outlines, “scientific investigations and studies for six technical elements:

- [e]arly investigations of the first identified cases/ clusters / outbreaks to identify potential sources of exposure, collection of samples at the source, define the characteristics of the novel pathogen involved for establishment of diagnostic assays;
- [h]uman studies: to understand the epidemiology including clinical presentation, modes of transmission, pathology, and earliest presence in syndromic surveillance samples;
- [h]uman/animal interface studies to identify potential animal reservoirs, intermediate hosts and reverse zoonoses;
- [s]tudies to identify insect vectors or other sources of infection as well as earliest presence in the environment;
- [g]enomics and phylogenetics studies to identify precursor strains, genomic characteristics, evolution in intermediate hosts and humans and spatial distribution over time; [and]
- [b]iosafety/biosecurity studies to determine if a breach in laboratory or research activities may have been associated with the first cases.”

The WHO further explained that, “[a]s each outbreak and pandemic demonstrates, human and animal health is threatened by the increasing risk of the emergence of known (such as Ebola, Nipah, avian influenza, Lassa and mpox viruses) and novel pathogens with epidemic and pandemic potential (novel influenza, MERS-CoV, SARS-CoV-1, SARS-CoV-2), the ability to prevent, and when we cannot prevent, to swiftly contain outbreaks and identify their origins is scientifically, morally, and financially more critical than ever.”

(Source: WHO [Announcement](#), 9/4/24) ♦

COMPANY NEWS

Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) [celebrated](#) the 19th annual Blood Collectors Week 2024 September 1st-7th. According to the news release, the initiative was co-created and is sponsored by the organizations and honors, “individuals who make blood collection possible — including phlebotomists, apheresis operators, medical directors, donor recruiters, technicians, and drivers — [for] their vital role as the connection between blood donors and patients relying on blood for optimal medical treatment.” Close to 300 collection sites across the U.S. were [anticipated](#) to take part in the year’s celebration.



(Source: Fresenius Kabi [News Release](#), 9/1/24)

A paper [published](#) in *Vaccines* investigates the potential of **Valneva**’s live-attenuated chikungunya virus (CHIKV) vaccine to offer “cross-protection” for other co-circulating alphaviruses. The researchers explained that, “vaccination elicits both homotypic and heterotypic neutralizing responses against three strains of CHIKV, O’nyong-nyong virus_{UGMP30}, Mayaro virus_{BeAr505411}, and Ross River virus_{T-48}. These responses were durable, with only a modest reduction in neutralization titer between one month and one year post-

(continued on page 7)



COMPANY NEWS (continued from page 6)

vaccination. This is important for the populations living in areas with not only CHIKV transmission but also potential for circulation of additional alphaviruses. Given that neutralizing antibodies are a correlate of protection for alphavirus infection in humans, these cross-neutralizing responses have potential to provide cross-protection to populations that are vulnerable to heterotypic alphavirus infection, although increasing antigenic differences between CHIKV and heterotypic alphaviruses may ultimately limit such cross-protective breadth.”

Citation: Weber, W, Streblow, Z., Kreklywich, C., *et al.* “[The Approved Live-Attenuated Chikungunya Virus Vaccine \(IXCHIQ®\) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.](#)” *Vaccines*. 2024.

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2024

Sept. 12. **FDA Grand Rounds – Advancing Blood Safety and Patient Health in HIV/AIDS through FDA’s Research on Viral Genome Surveillance, Diagnostic Technologies, and Biomarker Discovery (Webcast).** [Registration](#) is open. More information available [here](#).

Sept. 12-14. **Society for the Advancement of Patient Blood Management (SABM) 2024 Annual Meeting. Phoenix, Ariz.** [Registration](#) is open. More information available [here](#).

Sept. 16-18. **2024 FDA CBER Science Symposium (Hybrid), Silver Spring, Md.** [Registration](#) is open. More information available [here](#).

Sept. 17. **America’s Blood Centers (ABC) Webinar: Cybersecurity: Threats & Preventative Actions.** More information and a link to registration are available [here](#).

Sept. 18-19. **2024 ADRP Master Class: Bring in the Coach — The Path to Effective Leadership (Virtual).** More information available [here](#).

Sept. 19. **National Institutes of Health (NIH) Department of Transfusion Medicine NIH Clinical Center and the American Red Cross 43rd Annual Immunohematology and Blood Transfusion Symposium (Virtual).** [Registration](#) is open. More information available [here](#).

Sept. 24. **FDA Webinar: Labeling Requirements for *In Vitro* Diagnostic Products (IVD), Including Laboratory Developed Tests (LDTs), Under 21 CFR 809.10(b).** More information available [here](#).

Sept 26. **ABC Women’s Executive Leadership Community (WELC) Webinar: “Authentic Confidence.”** More information and a link to registration are [available](#) to ABC members.

Sept. 30-Oct. 3. **American Association of Tissue Banks (AATB) Annual Meeting. Denver, Colo.** [Registration](#) is open. More information available [here](#).

Oct. 16-17. **Biomedical Excellence for Safer Transfusion (BEST) Fall Meeting. Galveston, Texas.** More information available [here](#).

(continued on page 8)



CALENDAR (continued from page 7)

Oct. 19-22. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Houston, Texas.** More information available [here](#).

Oct. 28. **Centers for Disease Control & Prevention (CDC) Sickle Cell Data Collection (SCDC) Summit 2024 (Virtual).** [Registration](#) is open. More information available [here](#).

Oct. 30. **FDA Patient Engagement Advisory Committee Meeting on Patient-Centered Informed Consent in Clinical Study (Virtual).** More information available [here](#).

Nov. 6-7. **ABC Women's Executive Leadership Community (WELC) Workshop. San Antonio, Texas.** [Registration](#) is open. More information is available [here](#).

Nov. 13. **2024 ADRP International Showcase.** More information coming soon.

Nov. 19-20. **Trauma Hemostasis & Oxygenation Research (THOR) Network Emergency Transfusion in Females with Childbearing Potential: Mitigating the Risks of Hemolytic Disease of the Fetus and Newborn Meeting. Bethesda, Md.** [Registration](#) is open. More information available [here](#).

Nov. 19-20. **Plasma Protein Forum. Washington, D.C.** More information available [here](#).

2025

Mar. 10-12. **ABC Annual Meeting. Arlington, Va.** More information is coming soon.

May 6-8. **2025 ADRP Annual Conference. Oklahoma City, Okla.** More information available [here](#).

May 20-21. **International Plasma Protein Congress. Warsaw, Poland.** More information is coming soon.

Oct. 12-15. **AATB Annual Meeting. Atlanta, Ga.** More information is coming soon.

Oct. 25-28. **AABB Annual Meeting. San Diego, Calif.** More information is coming soon.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** More information coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Associate Medical Director (Oklahoma City, OK). Our Blood Institute (OBI) seeks an **Associate Medical Director** for its Oklahoma City headquarters location. The Associate Medical Director is a licensed physician with shared responsibility for the medical, technical, and clinical leadership and direction of OBI's operations. This position will help direct and supervise key staff and processes to ensure the safety and well-being of all blood donors, the quality of all blood products manufactured, and the provision of premier laboratory and patient services. Ample complex medical care and professional growth opportunities arise from our Therapeutic Apheresis, AABB accredited IRL, and FACT accredited cell

therapy operations. Numerous clinical research, public health, and product development initiatives can inspire projects ranging from community health surveillance to entrepreneurial start-ups. Empowering resources including clean rooms, a high-volume donor testing laboratory, and sizable software engineering skunkworks. OBI has a variety of outstanding opportunities to propel your career in a nimble, supportive, and friendly environment. Management experience and business skill acquisition is

(continued on page 9)



POSITIONS (continued from page 8)

guaranteed in a complex, 1100-employee non-profit organization. **Salary Range:** Competitive salary with excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. **How to apply:** <https://obi.org/about/careers/>.

Technical Director. The Northern California Community Blood Bank seeks a skilled leader and laboratory professional to join our team as Technical Director. Located in the magnificent Northern California coastal redwoods, Eureka is the market and cultural center of a beautiful region filled with iconic redwoods and stunningly beautiful, rugged remote ocean landscapes. Our blood bank offers a low-stress environment, excellent work-life balance, and the opportunity to join a supportive, inclusive team and an organization with a vibrant community relationship. The Technical Director has overall responsibility for the Laboratory and all activities related to the production of blood products. This position supervises Laboratory Staff performing component production, inventory control, distribution, and reference immunohematology, ensuring that all details of blood product manufacture are compliant with regulatory and standard-setting agencies. A qualified candidate must meet CLIA General supervisor qualifications and hold a California Clinical Laboratory Scientist License (CLS). Experience as a technologist performing high complexity testing in a clinical laboratory and familiarity with standard laboratory methods and techniques is required. For details and to apply, visit www.nccbb.net/employment.html.

Immunohematology Reference Lab Medical Technologist. LifeSouth Community Blood Centers is looking for an experienced Laboratory Medical Technologist, with a passion for making a difference, to join our Immunohematology Reference Laboratory team in Atlanta, GA. The position is responsible for following established policies and procedures, identifying problems that may adversely affect test performance or reporting of test results, and either correct the problems or immediately notify a supervisor, manager, or director. The IRL Medical Technologist will resolve immunohematology and compatibility problems to provide the safest donor blood for the patients in our community. We focus on providing the best possible customer service. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Immunohematology Reference Lab Medical Technologist. LifeSouth Community Blood Centers is looking for an experienced Laboratory Medical Technologist, with a passion for making a difference, to join our Immunohematology Reference Laboratory team in Jacksonville, FL. The position is responsible for following established policies and procedures, identifying problems that may

adversely affect test performance or reporting of test results, and either correct the problems or immediately notify a supervisor, manager, or director. This individual will resolve complex immunohematology and compatibility problems to provide the safest donor blood for the patients in our community. We focus on providing the best possible customer service. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

Laboratory Education Coordinator. LifeSouth Community Blood Centers is looking for a team-oriented, goal-driven individual with a passion for education to join the team as a Laboratory Education Coordinator in Gainesville, FL. This position is responsible for the overall execution and development of LifeSouth's Blood Banking and Transfusion Medical education programs. Additional responsibilities include assisting with the training of laboratory employees, assessing competencies, and maintaining training materials. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

IRL Supervisor. Bloodworks Northwest, a recognized leader in transfusion medicine, currently has an opening for an IRL Supervisor in the Immunohematology Reference Laboratory. Key responsibilities include supervising departmental staff, ensuring the management of departmental projects, and participating in interdepartmental projects according to established priorities and timelines. Coordinating quality review and management of errors. Providing technical expertise in IRL testing and the development and implementation of new methods and as needed and perform clinical laboratory testing. Requirements include: Must qualify as General Supervisor, High Complexity Testing, under CLIA personnel requirements found in Subpart M of the Code of Federal Regulations. Certification as a Specialist in Blood Banking (SBB) is required. Certification as a Medical Laboratory Scientist (MLS) is preferred. Five years of laboratory technical experience with at two years of experience in immunohematology reference testing is required or an equivalent combination of education and experience. Three years of laboratory supervisor or Lead experience is preferred. Demonstrated expertise in immunohematology reference testing. Basic knowledge of molecular techniques is preferred. We offer competitive benefits: Medical, dental, vision, life insurance, retirement plan, subsidized back-up childcare program, subsidized transit program, educational reimbursement and more! Interested candidates should apply directly on our website at www.bloodworksnw.org/careers

(continued on page 10)



POSITIONS (continued from page 9)



Assistant/Associate Director, Blood Transfusion Service (Massachusetts General Hospital; Boston, Massachusetts). The Department of Pathology at the Massachusetts General Hospital (MGH), a founding hospital of Mass General Brigham, and a major teaching affiliate of the Harvard Medical School, seeks a full-time, early- or mid-career, academically oriented transfusion medicine physician. The successful candidate will combine clinical and teaching activities with a research program in a field relevant to transfusion medicine, hematology, or hemostasis. The Blood Transfusion Service at MGH encompasses an FDA-licensed donor center, therapeutic apheresis, an outpatient transfusion/infusion clinic, a transfusion service, and progenitor cell collection and processing. We collaborate closely with colleagues in bone marrow and solid organ transplantation, CAR-T cell therapy, cardiac surgery, trauma and critical care, neurology, and pediatrics. Our faculty also work closely with transfusion medicine faculty within the MGB network. Service and teaching responsibilities will be shared with two full- and several part-time staff physicians. Candidates must be BC/BE in Transfusion Medicine, with primary training in either Pathology or Hematology/Oncology (adult or pediatric). Academic rank as Associate Professor, Assistant Professor or Instructor and salary will be commensurate with experience and accomplishments. Interested candidates should send a personal statement with research interest, three potential referees and Curriculum Vitae to: Dr. Robert Makar; Director, Blood Transfusion Service; Department of Pathology; Massachusetts General Hospital; 55 Fruit Street, GRJ 148; Boston, MA 02114. Email: rmakar@mgh.harvard.edu C/O Diane Savickas dsavickas@mgb.org. We are an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy, and pregnancy-related conditions, or any other characteristic protected by law.



**HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL**

